At the time of writing, Crinetics Pharmaceuticals Inc [CRNX] stock is trading at $31.88, up 4.49%. An important factor to consider is whether the stock is rising or falling in short-term value. The CRNX shares have gain 7.12% over the last week, with a monthly amount drifted -4.89%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Crinetics Pharmaceuticals Inc [NASDAQ: CRNX] stock has seen the most recent analyst activity on March 25, 2025, when Stifel initiated its Buy rating and assigned the stock a price target of $60. On February 04, 2025, Wolfe Research initiated with a Peer Perform rating. Jefferies upgraded its rating to a Buy but stick to its price target of $55 on January 22, 2025. Citigroup initiated its recommendation with a Buy and recommended $68 as its price target on March 06, 2024. Morgan Stanley started tracking with a Overweight rating for this stock on January 16, 2024, and assigned it a price target of $50. In a note dated December 21, 2023, Jefferies initiated an Hold rating and provided a target price of $35 on this stock.
For the past year, the stock price of Crinetics Pharmaceuticals Inc fluctuated between $24.10 and $62.53. Currently, Wall Street analysts expect the stock to reach $75.5 within the next 12 months. Crinetics Pharmaceuticals Inc [NASDAQ: CRNX] shares were valued at $31.88 at the most recent close of the market. An investor can expect a potential return of 136.83% based on the average CRNX price forecast.
Analyzing the CRNX fundamentals
Gross Profit Margin for this corporation currently stands at 0.01% with Operating Profit Margin at -495.7%, Pretax Profit Margin comes in at -431.91%, and Net Profit Margin reading is -431.91%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.31 and Total Capital is -0.29. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Crinetics Pharmaceuticals Inc [NASDAQ:CRNX] has a current ratio of 22.53. On the other hand, the Quick Ratio is 22.53, and the Cash Ratio is 1.65. Considering the valuation of this stock, the price to sales ratio is 8295.89, the price to book ratio is 2.38.
Transactions by insiders
Recent insider trading involved Pizzuti Dana, Chief Med and Dev Officer, that happened on Mar 19 ’25 when 2515.0 shares were sold. Chief Operating Officer, Knight Jeff E. completed a deal on Mar 19 ’25 to sell 7162.0 shares. Meanwhile, Chief Scientific Officer Betz Stephen F. sold 5770.0 shares on Mar 19 ’25.
